Chalcogen Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/424)
-
Publication number: 20090239867Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicant: ALLERGAN, INC.Inventor: David W. Old
-
Publication number: 20090239911Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 24, 2007Publication date: September 24, 2009Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky
-
Patent number: 7592364Abstract: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.Type: GrantFiled: February 7, 2007Date of Patent: September 22, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090233969Abstract: The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.Type: ApplicationFiled: May 27, 2009Publication date: September 17, 2009Applicant: DECODE GENETICS EHFInventors: Vincent Sandanayaka, Jasbir Singh, Mahnaz Keyvan, Michael David Krohn, Mark E. Gurney
-
Publication number: 20090227653Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: ApplicationFiled: May 15, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090227635Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, B, and J are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: February 27, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7585882Abstract: Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: wherein R1, R2, and R3 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.Type: GrantFiled: October 20, 2005Date of Patent: September 8, 2009Assignee: Memory Pharmaceuticals CorporationInventors: Allen Hopper, Robert Francis Dunn, Erik Mikal Kuester, Richard Dennis Conticello, Ruiping Liu, Ashok Tehim
-
Patent number: 7585887Abstract: The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing (a) cyclic ketoenols having the formula ?in which the groups W, X, Y, Z, A, B, D, and G have the meanings given in the disclosure, and (b) the active compounds (1) to (29) listed in the disclosure.Type: GrantFiled: October 29, 2001Date of Patent: September 8, 2009Assignee: Bayer CropScience AGInventors: Reiner Fischer, Christoph Erdelen
-
Publication number: 20090215734Abstract: Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided.Type: ApplicationFiled: February 26, 2009Publication date: August 27, 2009Applicant: ELEVATION PHARMACEUTICALS, INC.Inventor: William Gerhart
-
Publication number: 20090215857Abstract: The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 29, 2006Publication date: August 27, 2009Applicant: Pfizer Products Inc.Inventors: Thomas Bruno Lanni, Scott Edward Lazerwith, Susan Mary Kult Sheehan, Anthony Jerome Thomas
-
Publication number: 20090215736Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.Type: ApplicationFiled: September 23, 2008Publication date: August 27, 2009Applicant: Vertex Pharmaceuticals, IncorporatedInventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
-
Publication number: 20090208437Abstract: Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in particular deodorant/antiperspirant preparations.Type: ApplicationFiled: December 27, 2005Publication date: August 20, 2009Applicant: BEIERSDORF AGInventors: Michael Woehrmann, Lara Terstegen, Stefan Biel, Thomas Raschke, Svenja-Kathrin Cerv, Werner Zilz, Sven Untiedt, Thomas Nuebel, Uwe Schoenrock, Heiner Max, Helga Biergiesser, Yvonne Eckhard, Heike Miertsch, Heike Foelster, Cornelia Meier-Zimmerer, Bernd Traupe, Inge Kruse
-
Publication number: 20090209491Abstract: The present invention relates to inhibitors of post-proline cleaving enzyme, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention incorporate a lactam ring in the backbone of the inhibitors. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the target protease.Type: ApplicationFiled: February 23, 2005Publication date: August 20, 2009Applicant: Trustees of Tufts CollegeInventors: William W. Bachovchin, Hung-Sen Lai
-
Publication number: 20090209502Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.Type: ApplicationFiled: June 28, 2007Publication date: August 20, 2009Inventors: Barbara Haeberlin, Frank Stowasser, Wolfgang Wirth, Anton Baumberger, Stephan Abel, Sebastian Kaerger, Thomas Kieckbusch
-
Patent number: 7576102Abstract: The present invention relates to a chemical genus of biaryl substituted nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.Type: GrantFiled: August 3, 2006Date of Patent: August 18, 2009Assignee: deCODE genetics ehfInventors: Vincent Sandanayaka, Jasbir Singh, Mahnaz Keyvan, Michael David Krohn, Mark E. Gurney
-
Publication number: 20090203739Abstract: The invention provides compounds, pharmaceutical compositions and uses of compounds of general formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat an inflammatory disorder; wherein z X is 1, 2 or 4; X is —CO—Yk—(R1)n or SO2—Yk—(R1)n; k is 0 or 1; Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or is a cycloalkenyl or polycycloalkenyl group; each R1 is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms (for example of 5 to 20 carbon atoms, of 8 to 20 carbon atoms, of 9 to 20 carbon atoms, of 10 to 18 carbon atoms, of 12 to 18 carbon atoms, of 13 to 18 carbon atoms, of 14 to 18 carbon atoms, of 13 to 17 carbon atoms); or each R1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical; and n is any integer from 1 to m,Type: ApplicationFiled: June 14, 2006Publication date: August 13, 2009Inventors: David J. Grainger, David John Fox
-
Patent number: 7569598Abstract: The present invention relates to a process for the enrichment of the R,R- or S,S-configured glycopyrronium isomers and their thienyl derivatives having the R,S or S,R configuration.Type: GrantFiled: December 18, 2003Date of Patent: August 4, 2009Assignee: Meda Pharma GmbH & Co. KGInventors: Christian Noe, Martin Walter
-
Publication number: 20090192120Abstract: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP.Type: ApplicationFiled: June 24, 2008Publication date: July 30, 2009Applicant: MUSC Foundation for Research DevelopmentInventor: Inderjit Singh
-
Publication number: 20090192191Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutically useful compositions as MMP and TNF inhibitors.Type: ApplicationFiled: January 7, 2005Publication date: July 30, 2009Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Pravin S. Thombare
-
Publication number: 20090186834Abstract: Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.Type: ApplicationFiled: March 24, 2006Publication date: July 23, 2009Applicant: MICROBIA, INC.Inventors: John Talley, Eduardo Martinez, Daniel Zimmer, Regina Lundrigan
-
Publication number: 20090176799Abstract: Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula I: wherein R1, R2, and R3 are as defined herein.Type: ApplicationFiled: December 1, 2008Publication date: July 9, 2009Inventors: Liu Ruiping, Mike De Vivo, Hans-Jurgen Ernst Hess, Allen Hopper, Erik Kreuster, Ashok Tehim
-
Patent number: 7557137Abstract: There is provided a series of novel substituted gamma-lactams of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present invention is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.Type: GrantFiled: August 4, 2003Date of Patent: July 7, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Carl P. Decicco, Andrew J. Tebben, Lorin A. Thompson, III, Andrew P. Combs
-
Publication number: 20090170870Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X?, X?, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: December 12, 2008Publication date: July 2, 2009Inventors: YuHua Ji, Craig Husfeld, Rick Lee, YongQi Mu, Cameron Smith
-
Patent number: 7550453Abstract: The invention relates particularly to 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof as a medicament, particularly as anti-cancer agents.Type: GrantFiled: May 24, 2007Date of Patent: June 23, 2009Assignee: Aventis Pharma SAInventors: Jidong Zhang, Neerja Bhatnagar, Jean-Marie Ruxer
-
Patent number: 7550502Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: GrantFiled: March 20, 2007Date of Patent: June 23, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7550448Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 11, 2007Date of Patent: June 23, 2009Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20090156562Abstract: The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may be achieved by either varying the concentration of fluorescein, or by combining fluorescein with another dye. The invention is also directed to methods involving the use of said pharmaceutical compositions.Type: ApplicationFiled: November 13, 2006Publication date: June 18, 2009Inventor: Peter D. Winch
-
Patent number: 7547685Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed herein. Details are provided herein. Compositions, methods, and medicaments related thereto are also disclosed.Type: GrantFiled: November 7, 2005Date of Patent: June 16, 2009Assignee: Allergan, Inc.Inventor: David W. Old
-
Publication number: 20090149448Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.Type: ApplicationFiled: November 22, 2005Publication date: June 11, 2009Applicant: ASTRAZENECA ABInventors: Lilian Alcaraz, Roger Victor Bonnert, Anthony Ronald Cook, Timothy Jon Luker, Rukhsana Tasneem Mohammed, Stephen Thom
-
Patent number: 7544676Abstract: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.Type: GrantFiled: November 9, 2006Date of Patent: June 9, 2009Assignee: Adolor CorporationInventors: Roland E. Dolle, Karin Worm
-
Publication number: 20090131508Abstract: The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies.Type: ApplicationFiled: June 7, 2006Publication date: May 21, 2009Applicant: UCB PHARMA, S.A.Inventor: Peter Verdru
-
Patent number: 7534790Abstract: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.Type: GrantFiled: November 21, 2007Date of Patent: May 19, 2009Assignee: Cardiome Pharma Corp.Inventors: Allen I. Bain, Gregory N. Beatch, Cindy J. Longley, Bertrand M. C. Plouvier, Tao Sheng, Michael J. A. Walker, Richard A. Wall, Sandro L. Yong, Jeff Jiqun Zhu, Alexander B. Zolotoy
-
Publication number: 20090123541Abstract: The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising: (a) a highly soluble high dose active ingredient consisting essentially of therapeutically effective amount of levetiracetam or a pharmaceutically acceptable derivative thereof, and (b) a rate controlling means comprising a rate-controlling agent and/or a coating selected from (i) a active ingredient permeable coating surrounding the unit dosage form, and (ii) an active ingredient impermeable coating covering one or more surfaces but not all the surfaces of the unit dosage form, wherein the composition is in the form of a compact tablet and the levetiracetam or a pharmaceutically acceptable derivative thereof is present in an amount ranging from about 55% to about 90% by weight of the tablet.Type: ApplicationFiled: February 22, 2006Publication date: May 14, 2009Applicant: Sun Pharmaceutical Industries LimitedInventors: Yashoraj Rupsinh Zala, Nitin Bhalachandra Dharmadhikari
-
Publication number: 20090124668Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.Type: ApplicationFiled: January 15, 2009Publication date: May 14, 2009Inventors: Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
-
Publication number: 20090117074Abstract: The invention relates to compounds of formula (I) which are effective inhibitors of histone deacetylases.Type: ApplicationFiled: April 7, 2006Publication date: May 7, 2009Applicant: NYCOMED GmbHInventors: Thomas Maier, Thomas Bar, Thomas Beckers, Astrid Zimmermann, Frank Dullweber, Volker Gekeler
-
Publication number: 20090118335Abstract: The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.Type: ApplicationFiled: March 30, 2007Publication date: May 7, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Atsushi Hasuoka, Terufumi Takagi, Masahiro Kajino, Haruyuki Nishida
-
Patent number: 7524879Abstract: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.Type: GrantFiled: June 4, 2007Date of Patent: April 28, 2009Assignee: Cardiome Pharma Corp.Inventors: Gregory N. Beatch, Bertrand M. C. Plouvier, Tao Sheng, Michael J. A. Walker, Richard A. Wall, Sandro L. Yong, Jeff Jiqun Zhu, Alexander R. Zolotoy
-
Publication number: 20090105256Abstract: Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: are described herein, as well as methods of making and using such prodrugs and pharmaceutical compositions containing such prodrugs.Type: ApplicationFiled: March 31, 2005Publication date: April 23, 2009Applicant: Cardiome Pharma Corp.Inventors: Lewis Siu Leung Choi, Doug Ta Hung Chou, Allen W. Davidoff, Adewale Eniale, Bertrand M.C. Plouvier
-
Publication number: 20090099154Abstract: Pharmaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, solvates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.Type: ApplicationFiled: June 29, 2006Publication date: April 16, 2009Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Kour Chand Jindal, Sukhjeet Singh, Sanjay Boldhane
-
Publication number: 20090099182Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 24, 2007Publication date: April 16, 2009Inventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, JR., Yanping Xu
-
Publication number: 20090088464Abstract: Merged compounds of ion channel modulating compounds, including, for example, merged compounds of the ion channel modulating compound of the following formula: (I) are described herein, as well as methods of making and using such merged compounds and pharmaceutical compositions containing such merged compounds.Type: ApplicationFiled: April 1, 2005Publication date: April 2, 2009Applicant: Cardiome Pharma Corp.Inventors: Lewis S.L. Choi, Doug Ta Hung Chou, Grace Jung, Bertrand M.C. Plouvier
-
Publication number: 20090082422Abstract: The present application describes deuterium-enriched levetiracetam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090082328Abstract: This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 9, 2008Publication date: March 26, 2009Inventors: Yingfu Li, Joachim Rudolph, Jacques P. Dumas, Daniel Auclair, Mario Lobell, Marion Hitchcock, Ingo Hartung, Marcus Koppitz, Dominic Brittain, Florian Puehler, Kirstin Petersen, Judith Guenther
-
Publication number: 20090075954Abstract: Soft anticholinergic esters of the formulas: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X? is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.Type: ApplicationFiled: June 12, 2008Publication date: March 19, 2009Inventor: Nicholas S. BODOR
-
Publication number: 20090069326Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 23, 2007Publication date: March 12, 2009Inventors: John Gordon Allen, Alexei Pavlovych Krasutsky, Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
-
Publication number: 20090069335Abstract: The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y?, Y?, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: September 5, 2008Publication date: March 12, 2009Inventors: YuHua Ji, Craig Husfeld, YongQi Mu, Rick Lee, Li Li
-
Publication number: 20090069404Abstract: The present application describes deuterium-enriched vemakalant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 31, 2008Publication date: March 12, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090060922Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.Type: ApplicationFiled: August 22, 2008Publication date: March 5, 2009Applicant: Sepracor Inc.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
-
Publication number: 20090062372Abstract: A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation.Type: ApplicationFiled: March 20, 2006Publication date: March 5, 2009Inventor: Andrew Douglas Baxter
-
Publication number: 20090060917Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.Type: ApplicationFiled: August 21, 2008Publication date: March 5, 2009Applicant: Sepracor Inc.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar